Institut de Recherche Saint-Louis (IRSL)

What Institut de Recherche Saint-Louis (IRSL) does

The Institut de Recherche Saint-Louis (IRSL – UMR 1342) is a French public research institute created in 2025 through the merger of four prior research units, operating under the joint supervision of Université Paris Cité (UPC) and Inserm with select teams additionally labeled by CNRS (EMR8000), CEA, and Collège de France. Headquartered at 5 rue Thomas Mann in Paris's 13th arrondissement and anchored on the Campus Saint-Louis alongside Hôpital Saint-Louis (AP-HP), the institute comprises approximately 49 staff organized into roughly twenty research teams focused on onco-hematology (leukemias, therapeutic targeting, clinical trials), immunology and inflammation, dermatology, and infectious diseases. Several teams hold ATIP-Avenir or ERC labels, and the institute includes Pr Hugues de Thé, a Shaw Prize 2026 laureate.

IRSL's core offerings are organized around four technological platforms (flow cytometry, photonic microscopy, molecular biology, and the Plateforme d'Investigation Pré-Clinique for animal experimentation under national and European welfare regulations), a portfolio of coordinated transverse programs (IHU Institut de la Leucémie, SIRIC InSitu, RHU FAME and SPRINT, FHU TRANSVIR and PROTHEE), the European doctoral school HOB (Hématologie – Oncogenèse – Biothérapies), and the embedded Carnot Opale valorization institute for technology transfer. These resources support translational research, clinical trial coordination, cooperative oncology groups, and industry partnerships within the Campus Saint-Louis ecosystem that links research, hospital, education, patient associations, and industrial partners for personalized medicine.

IRSL does not operate a commercial revenue model. It is funded through French public sources — institutional tutelle (Inserm, Université Paris Cité), competitive national program grants (IHU, SIRIC, RHU, FHU), and doctoral-school support — with outputs disseminated through peer-reviewed publications, conference presentations, academic collaborations, technology transfer via Carnot Opale, and clinical application within Hôpital Saint-Louis. Its primary stakeholders are the academic medical research community: researchers, physicians, and clinicians conducting fundamental and translational work in its four areas of excellence.

Name

Institut de Recherche Saint-Louis (IRSL)

Legal name

Institut de Recherche Saint-Louis (IRSL)

Website

https://institutsaintlouis.univ-paris-diderot.fr

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

The Institut de Recherche Saint-Louis (IRSL – UMR 1342) is a French public research institute created in 2025 by merging four units under Université Paris Cité and Inserm, conducting translational research in onco-hematology, immunology, dermatology, and infectious diseases for the academic medical community.

Ownership category

akta.pro rank

Product category

Biomedical Research Institute

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYEDAHAGAI

Biomedical Sciences & Medical Research Institutes (University-Based)

Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

SECONDARYHLAGAEAB

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAFAMAL

Clinical Research & Trial Central Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYHLAGAIAE

Microscopy, Imaging & Flow Cytometry Instruments

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Equipment, Instruments & Consumables

SECONDARYHLAGAJAM

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAJAIAD

Disease-Specific Reference Laboratory Networks (e.g., TB, HIV, Influenza)

Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

Keywords

• Onco-hematology research
• Translational medicine
• Immunology research
• Preclinical investigation
• Biomedical research

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Marketing channels2 records

Core offering

IRSL conducts fundamental and translational research across four axes — onco-hematology (leukemias, breast cancer, myeloma, therapeutic targeting), immunology and inflammation, dermatology, and infectious diseases — through approximately twenty research teams. The institute operates shared technological platforms (flow cytometry, photonic microscopy, molecular biology, preclinical animal models), coordinates clinical trials and cooperative oncology groups, and delivers doctoral education via the European École Doctorale HOB. It also runs or hosts multiple transverse programs including IHU Institut de la Leucémie, SIRIC InSitu, RHU FAME and SPRINT, FHU TRANSVIR and PROTHEE, and the Carnot Opale valorization institute.

Product overview

The Institut de Recherche Saint-Louis (IRSL – UMR 1342) is a unified research institute created in 2025 under the dual supervision of Université Paris Cité and Inserm. It is not a commercial product company but rather a research organization offering scientific services through its ecosystem. The institute comprises approximately 20 research teams focused on onco-hematology, immunology, dermatology, and infectious diseases. Its core offerings include technological platforms (flow cytometry, photon microscopy, molecular biology, preclinical models), doctoral education (École Doctorale HOB), and transverse programs including IHU Institut de la Leucémie, SIRIC InSitu, RHU FAME and SPRINT, FHU TRANSVIR and PROTHEE, and the Carnot Opale valorization institute.

Differentiator

Problem solved

Functional benefit

Products and services

• IRSL Technological Platforms (Plateformes Technologiques de l'IRSL)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

15 partnerships are on record, tiered core, supporting and flagship.

• Université Paris Cité (UPC)coreStrategic or Co-development Partner · 1 January 2025One of two primary institutional tutelles (oversight bodies) of IRSL. UPC provides academic governance, doctoral programs including the European doctoral school 'Hématologie – Oncogenèse – Biothérapies' (HOB), and institutional support for research activities.
• Inserm (Institut national de la santé et de la recherche médicale)coreStrategic or Co-development Partner · 1 January 2025One of two primary institutional tutelles (oversight bodies) of IRSL. Inserm provides national health research oversight, funding coordination, and institutional validation of research programs.
• Hôpital Saint-Louis (AP-HP)coreStrategic or Co-development PartnerClinical partner hospital within Campus Saint-Louis. Enables translation of fundamental research findings into clinical applications and provides clinical research infrastructure. Located at 1 avenue Claude Vellefaux, 75010 Paris.
• CNRS (Centre National de la Recherche Scientifique)supportingStrategic or Co-development PartnerSome IRSL teams carry CNRS label (EMR8000). CNRS provides additional research framework and collaborative opportunities within the French research ecosystem.
• CEA (Commissariat à l'énergie atomique et aux énergies alternatives)supportingStrategic or Co-development PartnerSome IRSL teams carry CEA label, enabling collaboration in atomic energy and alternative energies research applications.
• Collège de FrancesupportingStrategic or Co-development PartnerSome IRSL teams carry Collège de France label, providing collaboration with France's premier institution for fundamental research, research teaching, and international scientific exchange.
• IHU Institut de la leucémieflagshipStrategic or Co-development PartnerInstitute Hospitalo-Universitaire dedicated to leukemia research and treatment. One of the flagship transverse programs coordinated by IRSL within Campus Saint-Louis ecosystem.
• SIRIC InSitucoreStrategic or Co-development PartnerSite de Recherche Intégrée sur le Cancer (Integrated Cancer Research Site) program coordinated by IRSL, supporting integrated cancer research activities.
• RHU FAMEcoreStrategic or Co-development PartnerHospitalo-Universitaire Research Program (Recherche Hospitalo-Universitaire) coordinated by IRSL as one of its transverse research initiatives.
• RHU SPRINTcoreStrategic or Co-development PartnerHospitalo-Universitaire Research Program (Recherche Hospitalo-Universitaire) coordinated by IRSL as one of its transverse research initiatives.
• FHU TRANSVIRsupportingStrategic or Co-development PartnerFédération Hospitalo-Universitaire focused on transversal research activities coordinated by IRSL.
• FHU PROTHEEsupportingStrategic or Co-development PartnerFédération Hospitalo-Universitaire focused on transversal research activities coordinated by IRSL.
• Carnot OpalesupportingStrategic or Co-development PartnerValorization institute hosted at IRSL for technology transfer and research valorization, supporting commercialization and industrial partnerships of research outputs.
• Patient AssociationssupportingStrategic or Co-development PartnerPatient associations hosted at IRSL contributing to patient-centered research, clinical trial design, and science outreach activities within Campus Saint-Louis.
• Science Promotion AssociationsupportingStrategic or Co-development PartnerAssociation for promotion of science hosted at IRSL, supporting public engagement and science-society relations activities.

Scale indicators3 records

Recent moves7 records

Expansion highlights3 records

Direct peers

• Centre de Recherche en Cancérologie de Lyon (CRCL): French cancer research center (Inserm/Université Claude Bernard Lyon 1/Centre Léon Bérard). Comparable as a French oncology-focused research unit under Inserm tutelle with platform-based translational research.
• Institut Pasteur: Paris-based foundational research institute covering infectious diseases, immunology, and developmental biology. Comparable as a French public research institute under mixed tutelle operating platform technologies and doctoral training programs alongside hospital translation.
• Institut Curie: Paris-based biomedical research center with dual hospital-research-care model focused on oncology and translational medicine. Directly comparable as a university/Inserm-affiliated cancer research institute with integrated clinical-hospital structure and platform technologies.
• Gustave Roussy Institute: Leading European cancer center combining research, treatment, and teaching. Comparable as a major Île-de-France oncology research and clinical-translation institution coordinating national cooperative oncology programs.
• Netherlands Cancer Institute (NKI): European cancer research institute combining fundamental research with clinical oncology in an integrated hospital-research setting. Directly comparable in scope, onco-hematology focus, and bench-to-bedside translational model.

Broad incumbents

• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization for life sciences across Europe. Comparable as a publicly funded multi-team research institution delivering platform technologies and training programs in molecular biology.
• Ludwig Institute for Cancer Research: International cancer research organization with multiple branches conducting fundamental and translational oncology research. Comparable in cancer research mission, multi-institutional structure, and translational pipeline orientation.
• Francis Crick Institute: Large biomedical discovery institute in London focused on fundamental research across cancer, immunology, and infectious diseases. Comparable as a publicly funded multi-team research center coordinating high-impact translational programs.
• French Institute of Health and Medical Research (Inserm): National public research institution overseeing biomedical research across France. Directly comparable as IRSL's parent tutelle and the broader institutional framework within which IRSL operates its research programs.
• German Cancer Research Center (DKFZ): Germany's largest biomedical research institute dedicated to cancer. Comparable as a publicly funded national-scale oncology research center coordinating large multi-program translational pipelines.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/irsl-institut-de-recherche-saint-louis

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut de Recherche Saint-Louis (IRSL)